Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial

Post time Half hour(s) ago

Seyed Reza Mirhafez 1, Maryam Dehabeh 1, Mitra Hariri 1, Azam Rezaie Farimani 1, Ali Movahedi 2, Ronika Danesh Naderan 1, Tannaz Jamialahmadi 3 4, Luis E Simental-Mendía 5, Amirhossein Sahebkar 6 7 8

PMID: 34981468
DOI: 10.1007/978-3-030-73234-9_2

Abstract

Background: Experimental and clinical studies have revealed that curcumin may be an effective therapy for non-alcoholic fatty liver disease (NAFLD). Hence, the aim of this study was to assess the effect of curcumin plus piperine administration on NAFLD.

Methods: Adults 18-65 years-old diagnosed with NAFLD by liver sonography were randomly allocated to curcumin (500 mg/day) or placebo groups for 2 months. All participants received both dietary and exercise advice. Anthropometric and biochemical measurements as well as hepatic ultrasound were performed at baseline and final conditions.

Results: Seventy-nine participants were recruited and randomly allocated into the curcumin (n = 39) or placebo (n = 40) groups. There were no significant differences between placebo and curcumin groups for demographic and clinical characteristics and NAFLD grade at baseline. After the treatment period, the curcumin group exhibited lower alkaline phosphatase (-16.2 ± 22.8 versus -6.0 ± 22.5 mg/dL, p = 0.04) concentrations and severity of NAFLD compared with the placebo group (p = 0.04).

Conclusion: Results of this clinical trial suggest that short-term treatment with curcumin plus piperine administration improves NAFLD severity.

Keywords: Clinical trial; Curcumin; Fatty liver disease; Piperine; Steatosis.

[Other] Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors